GAMMA Investing
FHTX icon

GAMMA Investing’s Foghorn Therapeutics FHTX Stock Holding History

GAMMA Investing’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.2K Sell
336
-299
-47% -$1.58K ﹤0.01% 4068
2026
Q2 		$3.1K Sell
635
-229
-27% -$1.02K ﹤0.01% 3638
2026
Q1 		$4.13K Buy
864
+500
+137% +$2.74K ﹤0.01% 3433
2025
Q4 		$1.97K Buy
364
+109
+43% +$494 ﹤0.01% 3602
2025
Q3 		$1.25K Buy
+255
New +$1.35K ﹤0.01% 3564
2025
Q2 		– Sell
-96
Closed -$350 – 3818
2025
Q1 		$350 Sell
96
-15
-14% -$68 ﹤0.01% 3722
2024
Q4 		$524 Buy
+111
New +$809 ﹤0.01% 3566

Other funds holding FHTX

TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's FHTX Position: Q3 2026 in Review

GAMMA Investing reduced its Foghorn Therapeutics (FHTX) stake by 47% in Q3 2026, selling an estimated $1.58K and leaving 336 shares worth $1.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4068.

GAMMA Investing first reported a position in FHTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.13K in Q1 2026. 5 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

  • GAMMA Investing held 336 shares of Foghorn Therapeutics worth $1.2K as of Q3 2026.
  • GAMMA Investing sold 299 Foghorn Therapeutics shares in Q3 2026, an estimated $1.58K.
  • Foghorn Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4068 holding.
  • GAMMA Investing first reported a position in Foghorn Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GAMMA Investing's Foghorn Therapeutics position peaked at $4.13K in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.